Contact

News

News and presentations

Press releases, conference data and company news since our founding in 2019.

Scientific presentations

  1. Scientific presentations

    TCX-201 and TCX-101 data presented at AACR 2026

    Two posters at the AACR Annual Meeting 2026 in San Diego: the preclinical profile of first clinical candidate TCX-201 (Poster 5631) and TCX-101 as a trispecific T-cell engager (Poster 5584).

    AACR 2026 poster 5631 on TCX-201, with in vitro, in vivo, pharmacokinetic and toxicology panels
  2. Scientific presentations

    TCX-201 poster at PEGS Europe 2025 in Lisbon

    Poster A116 on TCX-201 at the Protein & Antibody Engineering Summit, November 11–13, 2025.

    Announcement of Tacalyx poster A116 on TCX-201 at PEGS Europe 2025 in Lisbon
  3. Scientific presentations

    Talk at PEGS Boston 2025: targeting TACAs with high-affinity antibodies

    Dr. Peter Sondermann speaks in the oncology stream of the Protein & Antibody Engineering Summit on May 14, 2025.

    Announcement of Dr. Peter Sondermann's talk on targeting tumor-associated carbohydrate antigens at PEGS Boston 2025
  4. Scientific presentations

    Two TACA antibodies, two modes of action: TCX-201 and TCX-101 at AACR 2025

    Poster 1581 in Chicago: TCX-201 as an ADC against a fast-internalizing TACA, TCX-101 as a T-cell engager against a slow-internalizing one.

    Announcement of Tacalyx poster 1581 at the AACR Annual Meeting 2025 in Chicago
  5. Scientific presentations

    Two posters at the EORTC-NCI-AACR Symposium 2024

    Dr. Wiebke Winkler and Dr. Gustavo Schmidt Moreira present Tacalyx data at ENA 2024 in Barcelona, October 23–25.

    Announcement of two Tacalyx posters at the 36th EORTC-NCI-AACR Symposium in Barcelona, October 2024
  6. Scientific presentations

    TCX-101 preclinical data presented at AACR 2024

    Poster 3125: TCX-101, a novel antibody-drug conjugate targeting a tumor-associated carbohydrate antigen for the treatment of solid tumors.

    AACR 2024 poster 3125 on TCX-101 as an antibody-drug conjugate

Media inquiries: contact